Quest PharmaTech (CVE:QPT) Shares Down 25% – Here’s Why

Quest PharmaTech Inc. (CVE:QPT) fell 25% on Thursday . The company traded as low as C$0.03 and last traded at C$0.03. 123,238 shares traded hands during mid-day trading, an increase of 414% from the average session volume of 23,982 shares. The stock had previously closed at C$0.04.

Quest PharmaTech Stock Down 25.0%

The firm has a market cap of C$5.07 million, a price-to-earnings ratio of -30.00 and a beta of 0.00. The company has a quick ratio of 0.52, a current ratio of 0.40 and a debt-to-equity ratio of 4.35. The firm has a 50 day moving average of C$0.04 and a 200 day moving average of C$0.04.

About Quest PharmaTech

Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.